Related Articles
BNP as a marker for early prediction of anthracycline‑induced cardiotoxicity in patients with breast cancer
Visnagin: A novel cardioprotective agent against anthracycline toxicity (Review)
Cardiotoxicity of anthracycline‑free targeted oncological therapies in HER2‑positive breast cancer (Review)
Incidence of trastuzumab‑induced cardiotoxicity and impact of body mass index in patients with breast cancer: Results from a Saudi tertiary cancer center
Pegylated liposomal doxorubicin: Pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (Review)